Nevro shares are trading lower after the company reported worse-than-expected Q2 sales results. Also, Piper Sandler maintained an Underweight rating on the stock and lowered its price target from $12 to $7.
Portfolio Pulse from Benzinga Newsdesk
Nevro shares are trading lower after the company reported worse-than-expected Q2 sales results. Piper Sandler maintained an Underweight rating on the stock and lowered its price target from $12 to $7.
August 07, 2024 | 11:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nevro shares are trading lower due to disappointing Q2 sales results. Piper Sandler has maintained an Underweight rating and reduced the price target from $12 to $7.
The combination of worse-than-expected Q2 sales results and a lowered price target from a major analyst firm is likely to negatively impact Nevro's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100